His schemes have since become the industry standard.
 ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌


View this email in your browser
<[link removed]>

 

Dear reader,

You've heard of Martin Shkreli, the hedge fund manager
convicted of securities fraud who became infamous for buying a
lifesaving AIDS drug and increasing the price by 5,000 percent.
Shkreli's notoriety and subsequent conviction once seemed to suggest
that the government would actually do something about pharma
profiteering-but years later, it's clear that his scheme of
acquiring 'orphan drugs', or drugs to treat rare diseases that only
a few will ever need, and then hijacking prices, is now Big Pharma's
prevailing business model.

For the August 2023 print issue, Moe Tkacik details how Big Pharma's
drive for bigger and bigger profits has made business practices that
were once seen as outliers the industry standard. You can read the whole
story here.
<[link removed]>

This story is part of our ongoing series on the business of health
care-the inner workings of the monopolies and cartels extracting
ever-greater sums for ever-lousier outcomes, and the policies and
protocols pushing doctors and nurses to the brink-and increasingly
into labor unions. You can read the entire series here.
<[link removed]>

BUSINESS OF HEALTH CARE >>
<[link removed]>

Readers like
you make sure we have the ability to report on the stories that matter.
You can help support this work by becoming a member today
<[link removed]>. <[link removed]> All
of the support we receive funds our editorial mission: illuminating
stories about ideas, politics and power.

We can't do any of this without reader support. And if we don't do
it, there aren't many other places that will. Become a member today >>
<[link removed]>

I WANT TO SUPPORT THIS IMPORTANT
WORK >> <[link removed]>


Thanks for reading,

David Dayen
Executive Editor, The American Prospect

 

 

[link removed]

YOUR TAX DEDUCTIBLE DONATION SUPPORTS INDEPENDENT JOURNALISM
<[link removed]>

The American Prospect, Inc.
1225 I Street NW, Suite 600
Washington, DC xxxxxx
United States
Copyright (c) 2022 The American Prospect. All rights reserved.

To opt out of American Prospect membership messaging, click here
<[link removed]>.

To manage your newsletter preferences, click here
<[link removed]>.

To unsubscribe from all American Prospect emails, including newsletters,
click here
<[link removed]>.